Earnings Feed
Start Free
Home/Filings/4/0001209191-17-045120
4//SEC Filing

ChemoCentryx, Inc. 4

Accession 0001209191-17-045120

CIK 0001340652operating
View on SEC.govCompany Profile

Filed

Jul 12, 8:00 PM ET

Accepted

Jul 13, 7:46 PM ET

Size

51.5 KB

Accession

0001209191-17-045120

Insider Transaction Report

Form 4
Period: 2017-07-11
ChemoCentryx, Inc.CCXI
Bekker Petrus
SVP of Medical & Clinical
Transactions
  • Exercise/Conversion

    Common Stock

    2017-07-11$6.90/sh+23,876$164,744→ 83,715 total
  • Exercise/Conversion

    Common Stock

    2017-07-12$6.00/sh+10,000$60,000→ 69,839 total
  • Exercise/Conversion

    Common Stock

    2017-07-11$6.30/sh+6,124$38,581→ 65,963 total
  • Sale

    Common Stock

    2017-07-11$9.90/sh−23,876$236,372→ 59,839 total
  • Sale

    Common Stock

    2017-07-12$10.00/sh−10,000$100,000→ 59,839 total
  • Exercise/Conversion

    Common Stock

    2017-07-12$7.10/sh+6,997$49,679→ 66,836 total
  • Sale

    Common Stock

    2017-07-11$9.30/sh−6,124$56,953→ 59,839 total
  • Exercise/Conversion

    Common Stock

    2017-07-13$8.19/sh+12,125$99,304→ 71,964 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-12−1,250→ 2,500 total
    Exercise: $6.30Exp: 2020-08-10→ Common Stock (1,250 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-12−6,997→ 135,503 total
    Exercise: $7.10Exp: 2024-02-19→ Common Stock (6,997 underlying)
  • Sale

    Common Stock

    2017-07-13$10.19/sh−12,125$123,496→ 59,839 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-11−6,124→ 3,750 total
    Exercise: $6.30Exp: 2020-08-10→ Common Stock (6,124 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-12−9,253→ 4,092 total
    Exercise: $6.90Exp: 2021-08-04→ Common Stock (9,253 underlying)
  • Sale

    Common Stock

    2017-07-12$10.00/sh−2,500$25,000→ 59,839 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-13−12,125→ 179,375 total
    Exercise: $8.19Exp: 2025-02-23→ Common Stock (12,125 underlying)
  • Sale

    Common Stock

    2017-07-12$10.00/sh−1,250$12,500→ 59,839 total
  • Sale

    Common Stock

    2017-07-12$9.92/sh−9,253$91,810→ 59,839 total
  • Exercise/Conversion

    Common Stock

    2017-07-12$8.19/sh+2,500$20,475→ 62,339 total
  • Exercise/Conversion

    Common Stock

    2017-07-13$7.10/sh+3,888$27,605→ 63,727 total
  • Sale

    Common Stock

    2017-07-13$10.28/sh−3,888$39,969→ 59,839 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-11−23,876→ 13,345 total
    Exercise: $6.90Exp: 2021-08-04→ Common Stock (23,876 underlying)
  • Exercise/Conversion

    Common Stock

    2017-07-12$6.30/sh+1,250$7,875→ 61,089 total
  • Exercise/Conversion

    Common Stock

    2017-07-12$6.90/sh+9,253$63,846→ 69,092 total
  • Sale

    Common Stock

    2017-07-12$10.00/sh−6,997$69,970→ 59,839 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-12−10,000→ 0 total
    Exercise: $6.00Exp: 2019-02-17→ Common Stock (10,000 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-12−2,500→ 191,500 total
    Exercise: $8.19Exp: 2025-02-23→ Common Stock (2,500 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-07-13−3,888→ 131,615 total
    Exercise: $7.10Exp: 2024-02-19→ Common Stock (3,888 underlying)
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $9.90 to $10.00 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  • [F3]Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $10.00 to $10.37 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  • [F4]As of July 11, 2017, and prior to this transaction, the exercised options were fully vested.
  • [F5]Not applicable.

Documents

1 file

Issuer

ChemoCentryx, Inc.

CIK 0001340652

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001340652

Filing Metadata

Form type
4
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 7:46 PM ET
Size
51.5 KB
View on SEC.gov